argenex (NASDAQ:ARGX - Get Free Report) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a research note issued on Monday,Zacks.com reports.
A number of other equities research analysts have also recently weighed in on the stock. Wedbush restated an "outperform" rating and issued a $800.00 price objective on shares of argenex in a report on Monday, August 25th. Royal Bank Of Canada initiated coverage on argenex in a research report on Monday, August 25th. They issued an "outperform" rating and a $850.00 price target on the stock. Truist Financial upped their price target on argenex from $700.00 to $918.00 and gave the stock a "buy" rating in a research note on Monday, September 15th. Morgan Stanley lifted their price objective on argenex from $700.00 to $766.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Finally, HC Wainwright increased their target price on argenex from $720.00 to $774.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, argenex has a consensus rating of "Buy" and a consensus price target of $789.20.
Get Our Latest Stock Report on argenex
argenex Stock Down 0.8%
Shares of ARGX stock opened at $734.39 on Monday. The business's fifty day moving average is $675.85 and its 200 day moving average is $612.79. The stock has a market cap of $44.94 billion, a price-to-earnings ratio of 37.66, a PEG ratio of 0.81 and a beta of 0.41. argenex has a twelve month low of $510.05 and a twelve month high of $779.03.
argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $3.74 EPS for the quarter, beating the consensus estimate of $2.84 by $0.90. The business had revenue of $866.79 million during the quarter, compared to analyst estimates of $776.82 million. argenex had a return on equity of 21.06% and a net margin of 40.98%. Equities research analysts expect that argenex will post 3.13 earnings per share for the current fiscal year.
Hedge Funds Weigh In On argenex
Several institutional investors have recently made changes to their positions in ARGX. Rakuten Securities Inc. grew its position in argenex by 56.4% during the first quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock valued at $36,000 after buying an additional 22 shares during the period. WPG Advisers LLC bought a new position in argenex in the first quarter worth approximately $37,000. Golden State Wealth Management LLC purchased a new position in shares of argenex during the 1st quarter worth $44,000. Brooklyn Investment Group grew its position in shares of argenex by 102.7% during the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company's stock valued at $44,000 after acquiring an additional 38 shares during the period. Finally, MAI Capital Management increased its stake in shares of argenex by 866.7% in the 2nd quarter. MAI Capital Management now owns 87 shares of the company's stock worth $48,000 after purchasing an additional 78 shares in the last quarter. Institutional investors own 60.32% of the company's stock.
About argenex
(
Get Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider argenex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenex wasn't on the list.
While argenex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
